Table 2 Hematological adverse events according to CTCAE 4.0 by Ro-CHOEP cycles (number of cycles = 459).

From: Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study

 

Grade 1–2

Grade 3

Grade 4

Any type

41 (8.93)

63 (13.73)

156 (33.99)

Anemia

61 (13.29)

50 (10.89)

6 (1.31)

Leucopenia

6 (1.31)

19 (4.14)

43 (9.37)

Neutropenia

11 (2.4)

43 (9.37)

110 (23.97)

Thrombocytopenia

26 (5.66)

52 (11.33)

103 (22.44)

Febrile Neutropenia

7 (1.53)

10 (2.18)

11 (2.4)

  1. Data are n (%). CTCAE Common Terminology Criteria for Adverse Events.
Back to article page